BCM
AIMT

Beryl Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

Beryl Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-90,498
Closed -$3.12M – 264
2020
Q3 		$3.12M Buy
+90,498
New +$1.93M 0.56% 37

Beryl Capital Management's AIMT Position: Q4 2020 in Review

Beryl Capital Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 90,498 shares — an estimated $3.12M sold.

Beryl Capital Management first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $3.12M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Beryl Capital Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Beryl Capital Management sold 90,498 Aimmune Therapeutics shares in Q4 2020, an estimated $3.12M.
  • Beryl Capital Management first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
  • Beryl Capital Management's Aimmune Therapeutics position peaked at $3.12M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Beryl Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.